Loading...
•
Jun 30
Lantheus Q2 2025 Earnings Report
Lantheus reported its second quarter 2025 financial results, with a decrease in worldwide revenue but an increase in GAAP net income and EPS, while also announcing strategic acquisitions and a new stock repurchase program.
Key Takeaways
Lantheus experienced a slight decline in worldwide revenue in Q2 2025, primarily due to decreased PYLARIFY sales amidst increased competition. However, the company saw significant growth in GAAP net income and EPS. Strategic acquisitions of Life Molecular Imaging and Evergreen Theragnostics were completed, expanding the company's portfolio and capabilities. A new $400 million stock repurchase program was also authorized, reflecting confidence in long-term strategy.
Worldwide revenue for Q2 2025 was $378.0 million, a 4.1% decrease compared to the prior year.
GAAP fully diluted earnings per share increased by 27.3% to $1.12, while adjusted fully diluted earnings per share decreased by 12.8% to $1.57.
Net income rose by 26.9% to $78.8 million, and operating income decreased by 14.4% to $88.0 million.
The company completed key acquisitions of Evergreen Theragnostics and Life Molecular Imaging, expanding its radiopharmaceutical portfolio and capabilities, and announced FDA acceptance of a new formulation for piflufolastat F 18 PSMA PET imaging agent.
Lantheus
Lantheus
Lantheus Revenue by Segment
Revenue by Segment
PYLARIFY Sales Revenue
CapyFin.comDEFINITY Sales Revenue
CapyFin.comTechneLite Sales Revenue
CapyFin.comOther Precision Diagnostics Revenue
CapyFin.comStrategic Partnerships & Other Revenue
CapyFin.com Forward Guidance
Lantheus has updated its full-year 2025 corporate financial guidance, reflecting the impact of the Life Molecular Imaging acquisition and the current business outlook. The revised guidance indicates a lower revenue and adjusted EPS range compared to previous estimates.
Positive Outlook
- Completion of Life Molecular Imaging acquisition, immediately expanding growth profile and commercial portfolio with Neuraceq.
- FDA label expansion for Neuraceq in June, broadening its clinical indication.
- FDA acceptance of NDA for a new formulation of piflufolastat F 18 PSMA PET imaging agent, expected to increase batch size by ~50%.
- Board of Directors authorized a new $400 million stock repurchase program, demonstrating confidence in long-term strategy.
- Plans to submit an NDA for MK-6240, a next-generation tau imaging agent, in Q3 2025 after meeting primary endpoints in pivotal studies.
Challenges Ahead
- Updated full-year 2025 revenue guidance lowered to $1.475 billion - $1.51 billion from $1.550 billion - $1.585 billion.
- Updated full-year 2025 adjusted fully diluted EPS guidance lowered to $5.50 - $5.70 from $6.60 - $6.70.
- Increased competition in the PSMA PET landscape impacted PYLARIFY performance, leading to an 8.3% decrease in sales.
- Operating income decreased by 14.4% in Q2 2025.
- Adjusted fully diluted earnings per share decreased by 12.8% in Q2 2025.
Revenue & Expenses
Visualization of income flow from segment revenue to net income